What question did this study set out to answer?

Evaluate the real-world effectiveness and safety of dupilumab for treating patients with bullous pemphigoid.

October 17, 2024British Journal of DermatologyOpen Access

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series

View Full Paper

Ask AI

Bookmark

Authors

NPNidia Planella‐Fontanillas XBXavier Bosch‐Amate AAAlicia Jiménez Antón

Discussion

Member takes

Overview

Multicentre cohort study demonstrates high remission rates and steroid reduction with dupilumab in bullous pemphigoid, indicating an effective treatment alternative.

Key Points

Evaluate the real-world effectiveness and safety of dupilumab for treating patients with bullous pemphigoid.
Ambispective multicentre cohort study conducted across 34 hospitals including N=103 patients with bullous pemphigoid (median age 77.3 years; 58.3% male).
Patients received dupilumab (97.1% received a 600-mg loading dose followed by 300 mg every 2 weeks) as monotherapy or with concomitant therapy.
The primary endpoint was complete remission (CR; Investigator's Global Assessment score 0 or 1) at 4 weeks, with secondary outcomes evaluating CR at weeks 16, 24, and 52, itch scores, glucocorticoid tapering, and adverse events.
Complete remission was achieved by 53.4% of patients within 4 weeks and reached 95.7% by week 52.
Peak Pruritus Numerical Rating Scale scores decreased by 70.0% at week 4 and itch was completely controlled by week 24, while systemic glucocorticoid usage fell by 82.1% by week 52.
Adverse events occurred in 13 patients (mostly mild), with shorter disease duration and exclusive cutaneous involvement predicting better response at 16 weeks.

Cite This Study

Planella‐Fontanillas et al. (2024) studied this question.

synapsesocial.com/papers/6a85c7ea6f8d490ba41e8016 https://doi.org/10.1093/bjd/ljae403

View Full Paper

Ask AI

Bookmark

October 17, 2024British Journal of DermatologyOpen Access

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series

View Full Paper

Ask AI

Bookmark

Authors

NPNidia Planella‐Fontanillas XBXavier Bosch‐Amate AAAlicia Jiménez Antón

Discussion

Member takes

Overview

Multicentre cohort study demonstrates high remission rates and steroid reduction with dupilumab in bullous pemphigoid, indicating an effective treatment alternative.

Key Points

Evaluate the real-world effectiveness and safety of dupilumab for treating patients with bullous pemphigoid.
Ambispective multicentre cohort study conducted across 34 hospitals including N=103 patients with bullous pemphigoid (median age 77.3 years; 58.3% male).
Patients received dupilumab (97.1% received a 600-mg loading dose followed by 300 mg every 2 weeks) as monotherapy or with concomitant therapy.
The primary endpoint was complete remission (CR; Investigator's Global Assessment score 0 or 1) at 4 weeks, with secondary outcomes evaluating CR at weeks 16, 24, and 52, itch scores, glucocorticoid tapering, and adverse events.
Complete remission was achieved by 53.4% of patients within 4 weeks and reached 95.7% by week 52.
Peak Pruritus Numerical Rating Scale scores decreased by 70.0% at week 4 and itch was completely controlled by week 24, while systemic glucocorticoid usage fell by 82.1% by week 52.
Adverse events occurred in 13 patients (mostly mild), with shorter disease duration and exclusive cutaneous involvement predicting better response at 16 weeks.

Cite This Study

Planella‐Fontanillas et al. (2024) studied this question.

synapsesocial.com/papers/6a85c7ea6f8d490ba41e8016 https://doi.org/10.1093/bjd/ljae403

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark